Today: 21 November 2025
Subscribe
Browse Category

Investment Analysis News 17 October 2025 - 20 October 2025

BigBear.ai Stock Rockets 22% on New Defense AI Deal – Next Palantir or Passing Hype?

BigBear.ai Stock Rockets 22% on New Defense AI Deal – Next Palantir or Passing Hype?

BigBear.ai’s recent surge reflects both the promise of its cutting-edge tech and the risk of unmet expectations ts2.tech. Its Wall Street story is now “highly volatile,” with stock swings on every news cycle ts2.tech investing.com. Investors will be watching the Nov. 10 earnings closely: if the company can convert these new contracts into growing sales and improved margins, the bullish momentum could continue. If not, analysts warn, the stock (which currently has little earnings power baked in) may give back much of its gains. Sources: Company press releases ir.bigbear.ai ir.bigbear.ai; market reports and stock data investing.com ts2.tech ts2.tech markets.businessinsider.com; expert
20 October 2025
 ·  ·  ·  ·  · 
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

What to Know Before Markets Open on October 20, 2025 VKTX Stock Steadies After Volatile Stretch Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months. It ended Friday at $33.53 marketbeat.com, roughly flat on the week and not far from its intraday high of ~$36.80 on Thursday ir.vikingtherapeutics.com. This marks a dramatic recovery from mid-August, when VKTX plunged over 40% in one day following a crucial trial announcement ts2.tech. Back then, Viking had unveiled results from a Phase 2 study of its oral obesity pill that missed investor expectations, triggering a sharp selloff.
19 October 2025
 ·  ·  ·  ·  · 
Ford Stock Plunges Amid $1B Supplier Fire, EV Slump & Record Recalls – What’s Next?

Ford Stock Plunges Amid $1B Supplier Fire, EV Slump & Record Recalls – What’s Next?

Stock Performance in Recent Days Ford’s shares have been on a roller-coaster. After rallying near 52-week highs (around $12.00+ in late summer), the stock tumbled in early October on a cascade of bad news. As of the Oct. 17 close, Ford stock was about $11.92 ts2.tech. Analysts note the stock remains roughly 20–30% higher YTD ts2.tech, but volatility spiked after the aluminum-plant fire on Oct. 6 and the recall announcements. Trading volume has been unusually high (averaging >50 million shares/day in mid-Oct) ts2.tech, reflecting frantic buy/sell activity. Despite the swings, Ford looks “relatively cheap,” with a trailing P/E under 15
19 October 2025
 ·  ·  ·  ·  · 
Adobe Stock Tanks Near 52-Week Low – Is AI to Blame?

Adobe Stock Tanks Near 52-Week Low – Is AI to Blame?

Stock Performance As of mid-October 2025, ADBE is trading around $330 marketbeat.com. This level is near its 52-week lows (about $329) and far below 2024’s peak (~$555) ts2.tech. Over the past month the stock has fallen roughly 10–15%, and it is down about 20–25% YTD. Last week saw a small bounce (the stock was up ~1% on Oct 17) marketbeat.com, but the trend remains down. In technical terms, ADBE sits below both its 50-day and 200-day moving averages (recently ~$351 and ~$369, respectively marketbeat.com), reflecting its slide. The current valuation is relatively low: trailing P/E around 21x and forward P/E
19 October 2025
 ·  ·  ·  · 
Navitas (NVTS) Stock Skyrockets on NVIDIA AI Chip News — Record Rally Sparks Bull-Bear Debate

Navitas (NVTS) Stock Skyrockets on NVIDIA AI Chip News — Record Rally Sparks Bull-Bear Debate

NVTS Stock Rally and Recent Performance Navitas’s stock has exploded higher in mid-October. On Oct. 13 (Monday), NVTS jumped ~17–21% intraday after markets when the company announced new GaN/SiC power devices for NVIDIA’s next-gen data centers ts2.tech finviz.com. The rally accelerated each day: by Oct. 16 NVTS closed at $15.63, its highest ever, following five straight gains ts2.tech ts2.tech. Overall, Navitas shares nearly doubled in one week, climbing from roughly $8 to $15+ ts2.tech. Even on Oct. 17 the stock remained elevated (closing $14.66, down 6.2% for the day) stockanalysis.com. Daily/weekly trend: This October run is far above the stock’s
19 October 2025
 ·  ·  ·  ·  · 
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at the ESGCT conference – showed that a single dose of CTX460 delivered by lipid nanoparticles corrected the disease-causing mutation in >90% of liver cells and boosted functional AAT protein ~5-fold in animal models globenewswire.com. “The preclinical results demonstrate the potential of CTX460, developed using our novel SyNTase editing platform, to correct the mutation with precision and efficiency,” said CRISPR CMO
19 October 2025
 ·  ·  ·  ·  · 
NVIDIA 2025: Dominating the AI Boom – Company Overview, Key Segments, Competition, and Future Outlook

Nvidia’s $4 Trillion AI Frenzy: NVDA Stock Flirts with Record Highs Amid New Risks, Analysts See More Upside

NVDA Stock Rollercoaster Near Record Highs Nvidia’s stock (NASDAQ: NVDA) has been on a wild ride this month. Shares reached an all-time high around $195.62 in early October amid frenzied buying, only to reverse sharply a few days later ts2.tech. By Oct. 14, NVDA plunged over 4% in one session to roughly $180 as traders took profits and a broader tech sell-off hit high-flying names ts2.tech. The pullback was short-lived – by the end of the week the stock rebounded to the low-$180s, showing resilience after the mid-week dip ts2.tech. Nvidia is still trading near its peak levels, about 58%
18 October 2025
 ·  ·  ·  ·  · 
New Era Energy (NUAI) Stock Skyrockets on AI Data Center Pivot – Can the Rally Last?

New Era Energy (NUAI) Stock Skyrockets on AI Data Center Pivot – Can the Rally Last?

Key Stock Metrics: Metric Value (as of Oct 17, 2025) Closing Price $4.55 investing.com 1-Day Change +44.4% (vs $3.15 prev. close) stockanalysis.com Day’s Range $3.20 – $4.71 stockanalysis.com Volume (Oct 17) 33.82 million stockanalysis.com Market Cap ~$129.3 million investing.com 52-Week Range $0.32 – $12.29 stockanalysis.com AI Data Center Pivot Fuels Wild Rally New Era’s stock has rocketed in October thanks to its high-profile push into AI data centers. Mid-September it rebranded from New Era Helium to New Era Energy & Digital, emphasizing its shift into “energy-enabled” digital infrastructure ts2.tech. The company’s 50/50 joint venture, Texas Critical Data Centers (TCDC), is
18 October 2025
 ·  ·  ·  · 
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range ($0.77 low) and about twice its price at the start of 2025 stockanalysis.com marketbeat.com. Trading volume and volatility have picked up – for instance, on Oct. 14 a massive spike in call-option activity (761% above average) coincided with bullish sentiment marketbeat.com. The stock’s YTD gain (~100%) far outpaces many small-cap biotechs. Technical platforms note SLS is in “uptrend” territory: the stock is well above its 20-day EMA ($1.89) and 50-day EMA ($1.81) tipranks.com, which TipRanks flags
18 October 2025
 ·  ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai (which is majority-owned by Roche reuters.com) to turn one of Chugai’s injectable rare-disease antibodies into a pill formulation. The news, coupled with the new funding, ignited a buying frenzy ts2.tech. By mid-day Friday, RANI was up ~180% on the session ts2.tech, markedly outpacing the broader market’s modest gains (the S&P 500 and Nasdaq Composite were each up only ~0.5% that day investing.com). Deal Details: Under the Chugai
18 October 2025
 ·  ·  ·  ·  · 
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2% on Friday, Oct. 17, to close at $122.81 stockanalysis.com stockanalysis.com. That rally marked a new 2025 high for the biotech stalwart and brings its year-to-date gain to roughly 45–47% ts2.tech. By comparison, the Nasdaq Biotechnology Index is up only in the single digits over the same period ts2.tech. The recent jump – adding billions to Gilead’s market cap – reflects
18 October 2025
 ·  ·  ·  ·  · 
IBM Stock Soars on Quantum Breakthrough and AI Revival – Key Updates (Sept 25, 2025)

IBM Stock Hits Multi-Year High on AI & Quantum Hype – Can the Rally Last?

IBM’s Big 2025 Rally Powered by AI Ambitions International Business Machines (NYSE: IBM) has staged a remarkable comeback in 2025. After languishing for much of the past decade, IBM’s stock has roared back to life, reaching levels not seen in years. It briefly hit an intraday high of ~$296 in late September when news of a quantum computing feat with HSBC sparked a 5% one-day jump ts2.tech ts2.tech. Even with a minor dip in mid-October, IBM trades only a few percent below that peak. Year-to-date, the shares are up roughly 28% (through mid-Oct) – a huge move for such a
17 October 2025
 ·  ·  ·  ·  · 
1 … 22 23 24 25 26 … 31
Go toTop